Why AnaptysBio Trounced the Market on Thursday
AnaptysBio (NASDAQ: ANAB) rose by just over 11% on Thursday, as a high-profile bank has become more optimistic on the stock, to put it lightly. J.P. Morgan analyst Anupam Rama upgraded his recommendation on AnaptysBio stock. Rama is basing his enthusiasm on the company's upcoming official data release for its phase 2 clinical trial of imsidolimab.